HoldsUp

Richard Horowitz

Richard Horowitz is a physician specializing in the diagnosis and treatment of Lyme disease, tick-borne coinfections, and chronic illness. His published research primarily focuses on treatment protocols for chronic Lyme disease and post-treatment Lyme disease syndrome, particularly evaluated through dapsone combination therapy regimens and the Multiple Systemic Infectious Disease Syndrome (MSIDS) model. Additionally, his work includes studies on diagnostic assays for babesiosis and clinical reports on therapies for COVID-19.

47 claims checked on air: 5 context 1 contradicted 8 overstated 19 supported 14 unverified

What they said on air - contradicted

6 citing their own research

0:30:35contradictedhighUndiagnosed Infections Are Silently Causing Chronic Disease!

Lecanemab lowered phosphorylated tau by 23% in clinical trials over nearly 7 years.

"And the drugs that are used for it, lecanemab, they lowered phosphorylated tau by 23% in almost 7 years." (said at 0:30:35)

The claim that lecanemab lowered phosphorylated tau by 23% over nearly 7 years is contradicted by clinical trial evidence. In the primary Phase 3 clinical trial (Clarity AD), lecanemab was evaluated over an 18-month (1.5-year) double-blind period, not 7 years. While lecanemab significantly reduced amyloid markers and slowed clinical decline compared with placebo at 18 months, published clinical trials and long-term pharmacodynamic modeling evaluate outcomes over 18 months to 4 years, making the claimed 7-year timeframe inaccurate.

Fact-checked episodes

Publications